Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Myriad Genetics (MYGN) Free Cash Flow (2016 - 2026)

Myriad Genetics has reported Free Cash Flow over the past 17 years, most recently at $5.9 million for Q4 2025.

Quarterly Free Cash Flow rose 96.67% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$13.8 million through Dec 2025, up 50.18% year-over-year, with the annual reading at -$13.8 million for FY2025, 50.18% up from the prior year.
Free Cash Flow was $5.9 million for Q4 2025 at Myriad Genetics, down from $18.3 million in the prior quarter.
Over five years, Free Cash Flow peaked at $64.7 million in Q1 2021 and troughed at -$64.7 million in Q4 2023.
The 5-year median for Free Cash Flow is -$20.1 million (2022), against an average of -$17.4 million.
Year-over-year, Free Cash Flow tumbled 533.71% in 2022 and then skyrocketed 753.57% in 2025.
A 5-year view of Free Cash Flow shows it stood at $5.1 million in 2021, then plummeted by 529.41% to -$21.9 million in 2022, then tumbled by 195.43% to -$64.7 million in 2023, then surged by 104.64% to $3.0 million in 2024, then surged by 96.67% to $5.9 million in 2025.
Per Business Quant, the three most recent readings for MYGN's Free Cash Flow are $5.9 million (Q4 2025), $18.3 million (Q3 2025), and -$16.4 million (Q2 2025).